Ultrasound Technology to Diagnose and Treat Cardiovascular Disease

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease.

Hila Goldman-Aslan says that early detection is the go-to strategy to prevent a significant cardiac incident or death. “And ultrasound is the leading modality to identify those abnormalities in the heart, and it’s been increasingly used in all kinds of settings. You can see an ultrasound and cardiac ultrasound being used at the point of care in the emergency rooms and the ICU.”

A 2020 article from the American College of cardiology notes a rise in cardiovascular disease. With one-third of global deaths in 2019 attributed to cardiovascular disease, it is critical to find preventative solutions to reduce these alarming numbers. And this situation is where AI can play an essential role. “Artificial intelligence is all about data,” says Yehudit Levi. “The health segment is unique in the sense that a lot of medical records have been collected through the years. Artificial intelligence software enables processing these masses of data.” The insights gleaned from all this data and knowledge, once made accessible to the medical staff, help highlight abnormalities that might otherwise prove difficult to detect.

DiA Imaging Analysis powered through Intel technology strives to allow for more efficient cardiovascular results and better treatment. “We see physicians looking for more automated procedures and processes to help them make better decisions based on more objective information,” Goldman-Aslan says. Until recently, the review of ultrasound images relied solely on the operator, which creates a layer of subjectivity. With AI analysis, the process becomes more objective and provides better information for the cardiovascular team to make decisions. The increase in cardiac procedures and a shortage of staff analysts available make DiA Imaging ultrasound analysis solutions integral.

“Improving the diagnostic time is super important,” Levi stresses. “It allows more patients to be diagnosed.” Together, DiA and Intel make these ultrasound capabilities scalable for healthcare.

Learn more about Health and Life Sciences by connecting with Yehudit Levi and Hila Goldman-Aslan on LinkedIn or visit: 

Intel Health and Life Sciences 

DiA Imaging Analysis 

 Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.  

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More